Abstract
Breast cancer is the most frequent tumor of women. The development of effective adjuvant therapy based on postoperative administration of short-term chemotherapy (4-6 months) or long-term hormone therapy (5 years) or both, significantly improved survival of patients. However, therapy of adjuvant/metastatic disease is still palliative with a very low probability to induce complete remission and definitive cure of disease. The relevant efforts of basic research to identify the key and selective molecular alterations, which sustain breast cancer growth and progression allowed the possibility to develop specific molecular target treatments. Trastuzumab, a humanized monoclonal antibody to HER-2, is the first molecular targeting agent approved for therapy of metastatic breast cancer, capable to significantly improve clinical outcome in combination with cytotoxic therapy. Recent preliminary data from randomized, prospective, clinical trials suggest that trastuzumab decreases the risk of early recurrence by 50% in patients with HER-2-positive disease. Other novel targeted treatments are in clinical evaluation, including antiangiogenic compounds (Bevacizumab, sunitinib, vatalanib, and others) and bi-functional drugs such as lapatinib (anti Her-2 and EGFR agent) showing promising activity. This review provides an updated overview of the status of development of targeted therapy in breast cancer, as well as the challenges related to the rational use of molecular targeting agents.
Keywords: Targeting therapy, breast cancer, trastuzumab, cyclooxygenase-2, bevacizumab
Current Pharmaceutical Design
Title: Targeted Therapy of Breast Cancer
Volume: 13 Issue: 5
Author(s): Raffaele Longo, Francesco Torino and Giampietro Gasparini
Affiliation:
Keywords: Targeting therapy, breast cancer, trastuzumab, cyclooxygenase-2, bevacizumab
Abstract: Breast cancer is the most frequent tumor of women. The development of effective adjuvant therapy based on postoperative administration of short-term chemotherapy (4-6 months) or long-term hormone therapy (5 years) or both, significantly improved survival of patients. However, therapy of adjuvant/metastatic disease is still palliative with a very low probability to induce complete remission and definitive cure of disease. The relevant efforts of basic research to identify the key and selective molecular alterations, which sustain breast cancer growth and progression allowed the possibility to develop specific molecular target treatments. Trastuzumab, a humanized monoclonal antibody to HER-2, is the first molecular targeting agent approved for therapy of metastatic breast cancer, capable to significantly improve clinical outcome in combination with cytotoxic therapy. Recent preliminary data from randomized, prospective, clinical trials suggest that trastuzumab decreases the risk of early recurrence by 50% in patients with HER-2-positive disease. Other novel targeted treatments are in clinical evaluation, including antiangiogenic compounds (Bevacizumab, sunitinib, vatalanib, and others) and bi-functional drugs such as lapatinib (anti Her-2 and EGFR agent) showing promising activity. This review provides an updated overview of the status of development of targeted therapy in breast cancer, as well as the challenges related to the rational use of molecular targeting agents.
Export Options
About this article
Cite this article as:
Longo Raffaele, Torino Francesco and Gasparini Giampietro, Targeted Therapy of Breast Cancer, Current Pharmaceutical Design 2007; 13 (5) . https://dx.doi.org/10.2174/138161207780162890
DOI https://dx.doi.org/10.2174/138161207780162890 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Re-Sensitizing Tumor Cells to Cancer Drugs with Epigenetic Regulators
Current Cancer Drug Targets Telomerase as a Cancer Target. Development of New Molecules
Current Topics in Medicinal Chemistry Subject Index to Volume 5
Current Drug Metabolism Targeting the Bone Microenvironment in Metastatic Castration-Resistant Prostate Cancer
Current Drug Targets Anticancer Perspectives on the Fungal-Derived Polyphenolic Hispolon
Anti-Cancer Agents in Medicinal Chemistry Interfacial Fast Release Layer in Monodisperse Poly (lactic-co-glycolic acid) Microspheres Accelerates the Drug Release
Current Drug Delivery Economics of Pharmacogenomics: Rethinking Beyond QALYs?
Current Pharmacogenomics and Personalized Medicine Mechanisms of ERK1/2 Regulation by Seven-Transmembrane-Domain Receptors
Current Pharmaceutical Design The Vicious Circle of Leptin and Obesity
Current Nutrition & Food Science The Role of α7 Nicotinic Acetylcholine Receptors and α7-Specific Antibodies in Neuroinflammation Related to Alzheimer Disease
Current Pharmaceutical Design Ceramide: Therapeutic Potential in Combination Therapy for Cancer Treatment
Current Drug Metabolism Pyrimidine Nucleosides in Molecular PET Imaging of Tumor Proliferation
Current Medicinal Chemistry Future Prospect of RNA Interference for Cancer Therapies
Current Drug Targets Polyphenols: Potential Future Arsenals in the Treatment of Diabetes
Current Pharmaceutical Design Silencing the Transcription Factor FOSL1 in Hyperproliferative HaCaT Cells Makes Them Susceptible to IFN-γ
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Working Towards the Development of Vaccines for the Treatment and Prevention of Early Breast Cancer
Current Cancer Therapy Reviews Theranostic Applications of Lutetium-177 in Radionuclide Therapy
Current Radiopharmaceuticals p53 Activation by Blocking Snail : A Novel Pharmacological Strategy for Cancer
Current Pharmaceutical Design The Potential of Natural Products as Effective Treatments for Allergic Inflammation: Implications for Allergic Rhinitis
Current Topics in Medicinal Chemistry Some Developments Regarding Functional Food Products (Functional Foods)
Current Nutrition & Food Science